板塊異動 | 恆生科技指數漲超5%,微盟集團漲17%創新高
uSMART盈立智投1月20日消息,週三港股午後,南向資金繼續加碼買入港股,截至14:51分,南向資金淨流入逾160億港元,繼續抱團港股科技股,恆生科技指數漲幅擴大至5%,成分股方面,鴻騰精密漲超18%,微盟集團、阿里健康均漲超16%,京東健康漲超12%,明源雲漲超10%,阿里巴巴-SW漲超9%,美團、貓眼娛樂、比亞迪電子漲超7%。
兩倍做多恆生科技指數的ETF(7226)漲近11%。


圖片來源:WIND
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.